Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy

Area of Science:

• Neuroscience
• Neuropathology

Background:

• Orexin is a neuropeptide crucial for arousal.
• Reduced orexin is linked to neurological conditions like narcolepsy and MSA.
• Perry syndrome, a rare hereditary neurodegenerative disease, presents with parkinsonism, depression, weight loss, and central hypoventilation, often accompanied by sleep disturbances.

Purpose of the Study:

• To investigate orexin immunoreactivity in Perry syndrome for the first time.
• To compare orexin levels in Perry syndrome with other neurodegenerative diseases and controls.

Main Methods:

• Quantitative assessment of orexin immunoreactivity in the nucleus basalis of Meynert.
• Analysis of three Perry syndrome cases, five frontotemporal lobar degeneration with motor neuron disease cases, five MSA cases, and five age-matched controls.
• Review of antemortem clinical data on sleep disturbances, including polysomnography.

Main Results:

• Orexin immunoreactivity was significantly reduced in Perry syndrome and MSA compared to controls.
• No significant reduction in orexin immunoreactivity was observed in frontotemporal lobar degeneration with motor neuron disease.
• Two of three Perry syndrome cases exhibited confirmed sleep apnea syndrome.

Conclusions:

• This study is the first to report reduced orexin immunoreactivity in Perry syndrome.
• The orexin reduction in Perry syndrome is similar to that observed in multiple system atrophy.
• Further research with larger cohorts is necessary to understand the mechanisms underlying orexin loss in these disorders.